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of  the  infection  in humans  is inconsistent  as the  disease  is  not  under  EU surveillance  but  subject  to
national  policies.
Abbreviations: EU/EEA, European Union and European Economic Area; MS, member state; HEV, Hepatitis E virus.
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Europe
Epidemiology
Surveillance
Zoonotic infections
Study:  Countries  were  asked  to  nominate  experts  and  to  complete  a standardised  questionnaire  about  the
epidemiological  situation  and surveillance  of HEV  in their  respective  EU/EEA  country.  This  study  reviewed
surveillance  systems  for human  cases  of HEV  in  EU/EEA  countries  and nominated  experts  assessed  the
epidemiology  in  particular  examining  the recent  increase  in  the number  of autochthonous  cases.
Results:  Surveillance  systems  and  case deﬁnitions  across  EU/EEA  countries  were  shown  to  be  highly vari-
able  and  testing  algorithms  were  unreliable.  Large  increases  of autochthonous  cases  were  reported  from
Western  EU/EEA  countries  with  lower  case  numbers  seen  in Northern  and Southern  European  countries.
Lack of clinical  awareness  and  variability  in  testing  strategies  might  account  for the  observed  differences
in hepatitis  E incidence  across  EU/EEA  countries.  Infections  were  predominantly  caused  by  HEV  genotype
3, the most  prevalent  virus  type  in the  animal  reservoirs.
Conclusion: Discussions  from  the  expert  group  supported  joint  working  across  countries  to  better  monitor
the epidemiology  and  possible  changes  in  risk  of  virus  acquisition  at a European  level.  There  was  agree-
ment  to  share  surveillance  strategies  and  algorithms  but also  importantly  the collation  of  HEV  data  from
human  and  animal  populations.  These  data  collected  at a  European  level  would  serve  the  ‘One  Health’
approach  to better  informing  on human  exposure  to  HEV.
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a. Objectives
Hepatitis E virus (HEV) is one of the most common causes of hep-
titis worldwide [1]. HEV is endemic in regions of Asia and Africa
here it causes an acute self-limiting hepatitis in young adults,
xcept in pregnant women who have a case fatality rate of approx-
mately 25%. In these regions, infection is usually linked to HEV
enotypes (gt) 1 and 2 which are spread faecal-orally via contam-
nated water, resulting in both sporadic cases and large outbreaks
1].
Until a decade ago, cases of hepatitis E in Europe were thought to
e restricted to travellers returning from endemic areas. However,
t is now well-established that HEV is endemic in the EU/EEA [2].
ere, the virus is transmitted zoonotically with infections linked
ainly to gt3 viruses. Cases of acute hepatitis E caused by HEV
t3 occur mainly in older males and chronic infection in immuno-
uppressed individuals, including transplant recipients, have been
ecognised [1]. Excess mortality has not been observed in preg-
ant women in EU/EEA, but infection in patients with underlying
hronic liver disease has a reported case fatality rate of 27% [3].
owever, the burden of HEV infection in humans in Europe remains
oorly documented. HEV infection is not under EU surveillance, and
eporting systems, case deﬁnitions and populations under surveil-
ance are subject to national policies, which vary across countries.
ational incidence and prevalence estimates have been previously
ublished for a number of EU/EEA countries [4,5]. However, a
omparative EU-wide situational analysis has not previously been
eported. The aim of this study was to elucidate the emergence
f HEV infection in humans across the EU/EEA Member States by
eviewing the surveillance systems and reported number of hep-
titis E cases.
. Study
EU/EEA countries were invited to nominate national public
ealth experts, clinicians, and experts in blood safety working on
EV. In addition, a standardised questionnaire collected informa-
ion about national surveillance systems, and reported number of
ases of hepatitis E.
. ResultsInformation on surveillance systems was available from 29
ountries and experts from 17 countries contributed to the
ssessment of the epidemiological situation. A considerable hetero-© 2016  Published  by Elsevier  B.V.
geneity in surveillance arrangements, diagnostic testing algorithms
and case deﬁnitions between countries was  noted (Fig. 1, Table).
In 2014/15, increasing and large numbers of cases of HEV were
reported in France, Germany, England & Wales, the Netherlands,
and increases in Finland, Hungary and Italy (Table 1, Fig. 2).
Data from France, Germany, England & Wales, and the
Netherlands indicated more hepatitis E case notiﬁcations than hep-
atitis A cases (data not shown). Considerably lower numbers of
cases of hepatitis E were conﬁrmed in Northern and Southern Euro-
pean countries (Table 1).
In EU/EEA, infections were predominantly autochthonous and
caused by HEV gt3, the most prevalent virus type in humans and
animal reservoirs in Europe [6,7]. Viruses detected in England &
Wales between 2003 and 2009 were mainly gt3efg, while between
2010 and 2013, gt3c viruses predominated in humans. In contrast,
HEV from United Kingdom pigs tested in 2013 were gt3efg [8]. A
very small number of autochthonous cases caused by gt4 have been
documented in France and Italy.
Seroprevalence data were available in a minority of countries
and showed considerable heterogeneity possibly due to differences
in the performance of the assays used and in the characteristics
of the study population studied (data not shown). Data on HEV
viraemia in blood donations have been reported from several coun-
tries and showed a similar heterogeneity, ranging from 1:762 in the
Netherlands to 1:14,520 in Scotland [9,10].
4. Discussion
There has been a common trend amongst the Western Euro-
pean countries of a year on year increase in reported hepatitis E case
numbers. In some countries these numbers have exceeded reported
hepatitis A cases. This increase may  reﬂect a true rise in the inci-
dence of hepatitis E in some parts of Europe suggesting that there
has been a change in the risk of acquiring HEV. This is supported
by the observed increase in HEV RNA prevalence in blood donors
over time reported from England and the Netherlands [9,11–13].
The increase may  also be due to improved case-ascertainment:
clinicians are increasingly aware of HEV as a cause of hepatitis in
patients without a travel history, as suggested by the increased
numbers of tests performed for HEV in these countries. In Spain
and France, the number of tested specimens increased simultane-
ously to the rise of HEV cases, however, the positivity rate remained
constant (12%–17% in Spain).
The reason for the low numbers of cases in Northern and
Southern European countries is unknown. It could relate to differ-
ences in clinical awareness, diagnostic testing algorithms/criteria
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Table 1
Characteristics of hepatitis E surveillance systems in participating EU/EEA countries with number of cases and genotype/subtype.
Country Is HEV notiﬁable?
(Year)
Surveillance through reference
laboratory (period)
Case deﬁnition/positivity criteria Comments Number of reported cases of
Hepatitis E (autochthonous)
Predominant
autochthonous
HEV
genotype/subtype
Austria Yes 2014: 17 (15)
2015: 36 (30)
Belgium  Yes 2014: 35
2015: 65
Bulgaria No 2015: 54 gt3
Croatia  Yes 2014: 0
2015: 2
Czech Republic Yes (2008) Laboratory diagnosis
• Anti-HEV IgM, IgG
• HEV RNA in serum and stool
2014: 290 (288)
2015: 412 (398)
Denmark No Yes Diagnostics and typing performed at SSId. HEV
scheduled to become notiﬁable in 2016.
2014: 9 gt3
England  & Wales Yes
(2010)
Available at: https://www.gov.uk/
government/publications/hepatitis-e-
health-protection-response-to-
reports-of-infection
Viral hepatitis has been notiﬁable since the
1980’s. Hepatitis E has been notiﬁable since
2010. National guidelines on case deﬁnition
and testing algorithms are established.
2014: 886 (729)
2015: 848 (694)
gt3c
Estonia Yes
(1997)
First case notiﬁed in 2012. 2014: 1
2015: 1
gt3
Finland Yes
(1995)
Notiﬁcation criteria: serology, PCR. From the beginning of 2016, the laboratories
are encouraged to notify only anti-HEV
IgM-positive cases.
2014: 11
2015: 44
France No Yes
(2002–2014)
Diagnostic algorithm
Immunocompetent
• IgM(+) = recent infection to conﬁrm
by PCR
• IgM(−) = no recent infection
Immunocompromised
•  IgM(+) and HEV RNA(+) = recent or
active infection
Clearance or persistence by testing for
HEV RNA
• IgM(−) and HEV RNA(−) = no recent
infection
2014: 1825 (1813) gt3f
Germany Yes
(2001)
Notiﬁable are laboratory conﬁrmed
cases (IgM or IgG increase in paired
samples or PCR) with clinical
symptoms.
2014: 671
2015: 1266
gt3c
Greece No Based on a recent study of laboratory capacity
of Greek hospitals, hospital laboratories do not
test for HEV.
2003–2015: No reported clusters of HEV
infection.
Hungary Yes
(1993)
Conﬁrmed case: acute viral hepatitis
with positive anti-HEV IgM.
Reports based on syndromic surveillance.
Acute viral hepatitis is notiﬁable (infectious
hepatitis), testing is mandatory to determine
aetiology since 1993.
2014: 140 (140)
2015: 166 (166)
gt3
Iceland No
12
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Table 1(Continued)
Country Is HEV notiﬁable?
(Year)
Surveillance through reference
laboratory (period)
Case deﬁnition/positivity criteria Comments Number of reported cases of
Hepatitis E (autochthonous)
Predominant
autochthonous
HEV
genotype/subtype
Ireland Yes
(2015 Dec)
Clinical criteria: Not relevant for
surveillance purposes
Laboratory criteria:
Acute case: At least one of the
following two:
• HEV IgM and IgG antibody positive
•  Detection of HEV RNA
Chronic case: HEV RNA persisting for at
least 3 months.
2015: 30e
Italy Yes
(2007)
Clinical criteria: acute illness
compatible with hepatitis, and ALTa
>10 times the upper limit of the
normal range;
Serological criteria: IgM anti-HEV
positive, IgM anti-HBcb negative, IgM
anti-HAVc negative. Cases IgM
anti-HEV positive, in absence of clinical
signs, are included among “acute
hepatitis E cases”.
Italian surveillance for HEV is voluntary and
currently covers 77% of the Italian population.
2014: 18 (15)
2015: 22 (16)
gt3e, 3c, 3f
Latvia  Yes 2014: 16 (14)
2015: 10 (8)
Lithuania No
Luxembourg Yes
Malta No
Netherlands No Yes 2014: 142
2015: 200
gt3e (1%), 3c
(90%), 3e (1%),
3f (8%)
Norway  No 2014: 1
2015: 6
Poland  No 2014: 6 (4)
2015: 2 (2)
Portugal Yes
(2015)
Most cases are conﬁrmed by serology. 0
Slovakia Yes 2014: 16 (14)
2015: 27 (24)
Slovenia Yes 2014: 1 (1)
2015: 0
gt3
Spain  No Yes (2006–2015) PCR-positive or IgM and PCR-positive.
IgM positive without PCR: IgG
seroconversion is needed for
conﬁrmation.
80% of the territory is covered. 2014: 100
2015: 105 (103)
gt3f
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Sweden Yes
(1993)
Suspected case: Clinical illness
compatible with the diagnosis and an
epidemiological link to a
laboratory-conﬁrmed case.
Conﬁrmed case: A
laboratory-conﬁrmed case
Laboratory criteria (at least one of the
following two):
• Detection HEV speciﬁc
antibody-response in serum
indicating current infection.
•  Detection of HEV RNA in serum or
faeces.
2014: 22 (11)
2015: 29 (16)
The data shown are for the most recent year available, 2015 data might not be complete.
a ALT: alanine aminotransferase.
b anti-HBc: antibodies to hepatitis B core antigen.
c HAV: Hepatitis A virus.
d Statens Serum Institut.
e Report from the National Virus Reference Laboratory only.
14 C. Adlhoch et al. / Journal of Clinical Virology 82 (2016) 9–16
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pFig. 1. EU/EEA countries reporting sy
r surveillance systems/practices. Less exposure to HEV in such
ountries seems unlikely, given the estimated number of viaremic
lood donors in Spain [14] and the very high seroprevalence of
9% in blood donors in central Italy (unpublished data). In addi-
ion to differences between countries, there may  be differences in
iral pressure within a geographical region. In England, HEV sero-
revalence was 12–16% and 1:2848 blood donors were viraemic,
ompared to Scotland where seroprevalence was 5% and 1:14,520
onors were viaremic [10,11,15].
The number of laboratory-conﬁrmed/notiﬁed cases is almost
nvariably an underestimate of true incidence and this ‘tip-of-the-
ceberg’ effect is likely to be particularly pronounced with respect
o HEV [16,17]. Poor clinical awareness of the differential diagnosis
n patients with hepatitis might contribute to the underestimation
f symptomatic infection. Hepatitis E may  be frequently misdiag-
osed as drug-induced liver injury [18]. Finally, recent data have
hown that HEV infection may  present with a range of neurological
ymptoms, including Guillain–Barré syndrome, neuralgic amyotro-
hy and meningo-encephalitis [19]. Such patients are currently
ot routinely tested for HEV. Thus, the numbers of laboratory-
onﬁrmed cases documented here are likely to be underestimates
f the true incidence of clinical cases as suggested by data on num-
ers of viraemic blood donors.
The increased awareness and better testing systems might have
ontributed to the reported increase of locally acquired cases
ecently, but does not explain the recent replacement of predom-
nant virus subtypes gt3efg by gt3c in humans with a continued
irculation of gt3efg in the local pig population in the United King-
om, while in the Netherlands gt3c is detected in both, humans
nd pigs. HEV is highly prevalent in European pig herds [20] and
onsumption of contaminated pork products is one major risk fac-
or for human infection [17,21]. Monitoring activities in the food
roduction chain for HEV need to be enhanced to identify sources for hepatitis E virus infection, 2016.
of infection. To understand the relationship of human and animal
virus types across Europe, trade relations and the compilation of
food ingredients should be reviewed.
Our understanding of the epidemiology of HEV and its burden
of human infections at the EU/EEA level is currently inconsistent.
Increasing numbers of laboratory-conﬁrmed autochthonous cases
in many Western European countries suggest a common trend and
possibly common risks e.g. due to eating habits. Clinical testing
algorithms and numbers of diagnostic assays performed need to be
known to be able to put the data into perspective. A common EU-
wide strategy to better understand case numbers and determine
circulating strains of the virus across human and animal popula-
tions employing a ‘One Health’ approach are needed to address
these issues. The development of a joint sequence database cov-
ering also clinical data would be one suggestion.
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